| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash flows from financing activities | 3,261 | 3,261 |
| Net increase (decrease) in cash, cash equivalents | 847 | 1,788 |
| Cash and cash equivalents at beginning of period | 1,091 | - |
| Cash and cash equivalents at end of period | 1,938 | - |
Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. (TCRT)